Corvus Pharmaceuticals (FRA:C17) Cyclically Adjusted Book per Share: €2.57 (As of Mar. 2026)


FRA:C17 Corvus Pharmaceuticals Inc FRA:C17
34 GF Score
Price €13.26
! 1 Warning Sign
View Full Analysis

What is Corvus Pharmaceuticals Cyclically Adjusted Book per Share?

Corvus Pharmaceuticals FRA:C17 +5.57% 34 Cyclically Adjusted Book per Share is €2.57 as of Mar. 2026. GuruFocus rates FRA:C17 with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Corvus Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was €2.476. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €2.57 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Corvus Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 3.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-05), Corvus Pharmaceuticals's current stock price is €13.26. Corvus Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €2.57. Corvus Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 5.16.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Corvus Pharmaceuticals was 4.61. The lowest was 0.00. And the median was 0.00.


Corvus Pharmaceuticals  (FRA:C17) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Corvus Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=13.26/2.57
=5.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Corvus Pharmaceuticals was 4.61. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Corvus Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Corvus Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Corvus Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corvus Pharmaceuticals Cyclically Adjusted Book per Share Chart

Corvus Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 3.03 2.76

Corvus Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.10 2.63 2.77 2.76 2.57

FRA:C17 vs LXRX, CGEM, WVE: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Corvus Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corvus Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corvus Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Corvus Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


FRA:C17
34GF Score
Corvus Pharmaceuticals Inc FRA:C17
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corvus Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Corvus Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.476/330.2130*330.2130
=2.476

Current CPI (Mar. 2026) = 330.2130.

Corvus Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 6.469 241.018 8.863
201609 6.089 241.428 8.328
201612 6.017 241.432 8.230
201703 5.280 243.801 7.151
201706 4.455 244.955 6.006
201709 3.755 246.819 5.024
201712 3.407 246.524 4.564
201803 3.814 249.554 5.047
201806 3.735 251.989 4.894
201809 3.478 252.439 4.550
201812 3.307 251.233 4.347
201903 3.039 254.202 3.948
201906 2.704 256.143 3.486
201909 2.483 256.759 3.193
201912 2.290 256.974 2.943
202003 1.944 258.115 2.487
202006 1.610 257.797 2.062
202009 1.281 260.280 1.625
202012 2.090 260.474 2.650
202103 2.070 264.877 2.581
202106 1.886 271.696 2.292
202109 1.920 274.310 2.311
202112 1.847 278.802 2.188
202203 1.750 287.504 2.010
202206 1.633 296.311 1.820
202209 1.403 296.808 1.561
202212 1.138 296.797 1.266
202303 0.980 301.836 1.072
202306 0.934 305.109 1.011
202309 0.846 307.789 0.908
202312 0.723 306.746 0.778
202403 0.626 312.332 0.662
202406 0.761 314.175 0.800
202409 0.179 315.301 0.187
202412 0.458 315.605 0.479
202503 0.669 319.799 0.691
202506 0.933 322.561 0.955
202509 0.819 324.800 0.833
202512 0.700 324.054 0.713
202603 2.476 330.213 2.476

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €2.57 mean?
Corvus Pharmaceuticals (FRA:C17) has a Cyclically Adjusted Book per Share of €2.57 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Corvus Pharmaceuticals and its competitors.
Is Corvus Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Corvus Pharmaceuticals' current Cyclically Adjusted Book per Share is €2.57. Overall, Corvus Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Corvus Pharmaceuticals' Cyclically Adjusted Book per Share compare to LXRX and CGEM?
Corvus Pharmaceuticals' Cyclically Adjusted Book per Share of €2.57 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Corvus Pharmaceuticals and its competitors. Corvus Pharmaceuticals's current Cyclically Adjusted Book per Share is €2.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corvus Pharmaceuticals stock overvalued right now?
Corvus Pharmaceuticals (FRA:C17) has a current Cyclically Adjusted Book per Share of €2.57. The current Cyclically Adjusted Book per Share is €2.57. Corvus Pharmaceuticals' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Corvus Pharmaceuticals (FRA:C17), the current Cyclically Adjusted Book per Share is €2.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corvus Pharmaceuticals Business Description

Other Exchanges CRVS:USAC17:Germany
Address 901 Gateway Boulevard, Third Floor, South San Francisco, CA, USA, 94080
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
34GF Score

Get the complete analysis for FRA:C17

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.26
Price